NATAUSHA SMITH: Open Payments
NPI 1912771056 · KENNETT, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$806 in 41 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $614 · 2025 $806
Food & beverage: $806
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 6 | $139 |
| E.R. Squibb & Sons, L.L.C. | 9 | $136 |
| Alkermes, Inc. | 6 | $116 |
| Lundbeck LLC | 4 | $105 |
| Otsuka America Pharmaceutical, Inc. | 5 | $80 |
| Teva Pharmaceuticals USA, Inc. | 3 | $67 |
| Vanda Pharmaceuticals Inc. | 3 | $57 |
| Janssen Pharmaceuticals, Inc | 2 | $41 |
| ABBVIE INC. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $28 |
Products named: INGREZZA, ARISTADA, COBENFY, REXULTI, ABILIFY ASIMTUFII, FANAPT, UZEDY, INVEGA SUSTENNA.
Industry payments across MO — which companies pay providers there.
